

Recombinant human Sclerostin, N-His-Avi (HEK293)

Catalog Number: bs-47201P

Concentration: >0.5 mg/ml

AA Seq: 24-213/213

Predicted MW: 24.2

Detected MW: Due to glycosylation, the protein migrates to 25-40 kDa based on Tris-Bis PAGE result.

Tags: N-His-Avi

Activity: Not tested

Endotoxin: <1.0 EU/μg as determined by LAL

Purity: >95% as determined by Tris-Bis PAGE

Purification: AC


Form: Lyophilized

Storage: Lyophilized from 0.22μm filtered solution in PBS (pH7.4) with 5mM DTT. Normally 5% trehalose is added as protectant before Lyophilization.


Stored at -70°C or -20°C. Avoid repeated freeze/thaw cycles.

Background: Negative regulator of bone growth. Sclerostin (SOST) is a bone morphogenetic protein (BMP) antagonist, leading to the activation of BMP signaling. It negatively regulates the formation of bone by repressing the differentiation and/or function of osteoblasts induced by BMPs. It has been shown that Sclerostin binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. The noggin-sclerostin protein complex represents a novel mechanism for the fine-tuning of BMP activity in bone homeostasis. Evidence is accumulating that one of the important mechanisms of bone regulation by sclerostin is the modulation of Wnt/Beta-catenin signaling. Sclerostin also rapidly activated ERK-1/2 MAPK signaling, indicating the involvement of additional signaling pathways

VALIDATION IMAGES



Human SOST on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.



Immobilized Human SOST, His Tag at 0.2μg/ml (100μl/Well). Dose response curve for Anti-SOST Ab. with the EC50 of 15.4ng/ml determined by ELISA.